Glycosylation is a common modification reaction in natural product biosynthesis and has been known to be a post-assembly line tailoring process in glycosylated polyketide biosynthesis. Here, we show that in pactamycin biosynthesis, glycosylation can take place on an acyl carrier protein (ACP)-bound polyketide intermediate. Using in vivo gene inactivation, chemical complementation and in vitro pathway reconstitution, we demonstrate that the 3-aminoacetophenone moiety of pactamycin is derived from 3-aminobenzoic acid by a set of discrete polyketide synthase proteins via a 3-(3-aminophenyl)3-oxopropionyl-ACP intermediate. This ACP-bound intermediate is then glycosylated by an N-glycosyltransferase, PtmJ, providing a sugar precursor for the formation of the aminocyclopentitol core structure of pactamycin. This is the first example of glycosylation of a small molecule while tethered to a carrier protein. Additionally, we demonstrate that PtmO is a hydrolase that is responsible for the release of the ACP-bound product to a free β-ketoacid that subsequently undergoes decarboxylation.
G lycosylation is one of the most ubiquitous and important transformations in nature and plays a central role in the structural and physiological aspects of living organisms. Glycosyltransferases are the family of enzymes that catalyze glycosylation, resulting in sugar-containing products. In natural product biosynthesis, glycosylation is generally considered to be a tailoring process that takes place later in the pathway after the backbone structure is formed. Some exceptions apply to certain natural products when glycosylation is directly involved in the formation of the core structure. Such a phenomenon has been proposed to occur in the biosynthesis of at least two highly important microbial natural products, mitomycin and pactamycin [1] [2] [3] . Pactamycin (1) is a potent antitumor antibiotic produced by Streptomyces pactum American Type Culture Collection (ATCC) 27456 with a unique chemical structure having a highly decorated aminocyclopentitol core unit and 3-aminoacetophenone (3AAP, 2), 6-methylsalicylic acid (6MSA) and N,N-dimethylurea moieties (Fig. 1a) . It has been proposed that the core cyclopentitol unit is derived from glucose (Glc) or N-acetylglucosamine (GlcNAc), presumably through an unprecedented rearrangement mechanism 4 . The 3AAP moiety is derived from 3-aminobenzoic acid (3ABA, 3), a product of dehydroshikimic acid catalyzed by a unique PLP-dependent aminotransferase-aromatase enzyme, PtmT (Fig. 1b) , which is called PctV in another pactamycin cluster in S. pactum NBRC 13433 (Supplementary Table 1 ) [5] [6] [7] [8] . The 6MSA moiety is produced by the iterative type I polyketide synthase (PKS) PtmQ 3 . A number of tailoring processes, for example, amination, carbamoylation (urea formation), C-and N-methylations and hydroxylation, are involved in the pathway and result in a highly decorated aminocyclopentitol unit that is rich in stereocenters 9, 10 . Although direct involvement of 3ABA in pactamycin biosynthesis has been established 5, 6 , the process underlying its conversion to the 3AAP moiety is not well understood. On the basis of the putative functions of genes within the pactamycin cluster (Fig. 1c) , two plausible pathways to the 3AAP moiety have been proposed. The first one involves a putative AMP-forming acyl-CoA synthetase, PtmS, which may convert 3ABA to 3ABA-AMP, followed by coupling between 3ABA-AMP and acetyl-CoA to give β-ketoacyl CoA ester 2 . Hydrolysis of the β-ketoacyl CoA by a putative hydrolase/ acyltransferase (PtmO) followed by a decarboxylation reaction would give 3AAP (Fig. 1b , path I) 2 . The other pathway involves PtmS and discrete polyketide enzymes, PtmI (an ACP), PtmK (a β-ketoacyl-ACP synthase, KAS), and a putative hydrolase/acyltransferase, PtmO (Fig. 1b , path II) 3 . PtmK is similar to KAS I/II, which is responsible for the elongation steps in fatty acid biosynthesis 11, 12 . In this scenario, PtmS is proposed to activate 3ABA and load it onto the ACP PtmI, whereas PtmK is proposed to catalyze condensation between 3ABA-ACP and malonyl-ACP. The product is then cleaved from the ACP (PtmI) by the putative hydrolase/acyltransferase PtmO. However, no experimental evidence is available to support either of the above pathways.
The formation of the cyclopentitol unit in pactamycin is also unknown. Incorporation studies using isotopically labeled precursors have shown that this portion of the molecule is derived from glucose, likely via N-acetylglucosamine (GlcNAc) 4 . Available genetic information suggests that a radical S-adenosyl methionine-dependent enzyme (PtmC), a putative glycosyltransferase (PtmJ) and a putative deacetylase (PtmG) may be involved in the formation of the cyclopentitol core, and this process may be similar to the formation of the mitosane core structure during mitomycin biosynthesis [1] [2] [3] . In mitomycin biosynthesis, however, d-glucosamine (or its derivative) is assembled into the mitosane unit through condensation with 3-amino-5-hydroxybenzoic acid (AHBA). Although details for this reaction are not available, it has been proposed that MitB, a protein with similarity to PtmJ, mediates the condensation reaction, followed by an unknown mechanism to complete C-C bond formation 13 . In fact, the glycosyltransferase PtmJ from S. pactum has been shown to catalyze a coupling reaction between uridine diphosphate-N-acetyl-α-d-glucosamine (UDP-GlcNAc) and 3AAP 2 . The product would then need to undergo deacetylation, possibly by the N-deacetylase homologue PtmG followed by a radical-mediated rearrangement by PtmC to form the cyclopentitol ring structure. Inactivation of the ptmC and ptmJ genes indeed abolished the production of pactamycin, demonstrating their importance in the early biosynthetic steps 3 . Despite the ability of PtmJ to glycosylate 3AAP in vitro, our incorporation studies showed that 3AAP is not able to rescue the
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Auday A. Eida 1 production of pactamycin in the ΔptmT mutant strain of S. pactum, which lacks the ability to produce 3ABA 5 , suggesting that 3AAP is not a free intermediate in the pactamycin pathway. Consequently, the mode of formation of the 3AAP unit in pactamycin biosynthesis and the timing of the glycosylation reaction catalyzed by PtmJ remained unclear. Here, we employed in vivo gene inactivation, chemical complementation and in vitro pathway reconstitution using six purified recombinant proteins to interrogate the formation of the 3AAP unit of pactamycin and the timing of the glycosylation reaction. The results not only provided insights into the biosynthesis of pactamycin, but also revealed an interesting and unprecedented phenomenon where glycosylation occurs on a polyketide intermediate while it is still attached to a carrier protein.
results

Involvement of discrete PKS proteins.
To explore the role of ptmI, ptmK and ptmO in pactamycin biosynthesis, these genes were inactivated in a ΔptmH mutant strain that produces pactamycin analogs 14 TM-025 (4) and TM-026 (5) (Supplementary Figs. 1 and 2 ). The ΔptmH mutant was used because TM-025 and TM-026 are chemically more stable and produced in higher yields than pactamycin. Electrospray ionization-mass spectrometry (ESI-MS) analysis of the products revealed that inactivation of ptmI, ptmK or ptmO in the ΔptmH strain entirely abolished the production of TM-025 and TM-026 ( Supplementary Fig. 3 ). In addition, the mutants did not give any detectable intermediates, indicating that these gene products are involved early in the pathway 3, 14 . Chemical incorporation experiments with 3ABA in these mutants also did not give any products, consistent with the notion that these discrete PKS enzymes play a role in the conversion of 3ABA to the 3AAP moiety.
Evaluation of N-acetylcysteamine thioesters. Based on the above results, we hypothesized that 3ABA is activated by PtmS and loaded onto the ACP PtmI. Claisen condensation between 3ABA-ACP and malonyl-ACP catalyzed by PtmK would give 3-(3-aminophenyl)3-oxopropionyl-ACP (3AP-3OP-ACP). To test this hypothesis, N-acetylcysteamine (NAC) thioesters of 3ABA and 3-(3-aminophenyl)3-oxopropionate (3AP-3OP), which mimics the β-ketoacyl-ACP, were synthesized (Supplementary Note 1) and added to the cultures of the 3ABA-lacking ΔptmH/ΔptmT mutant 5 . ESI-MS and tandem MS analyses of the culture broths of the ΔptmH/ΔptmT mutant fed with 3ABA-SNAC (9) or 3AP-3OP-SNAC (12) revealed the recovery of TM-025/TM-026 production by the mutant (Fig. 2a-f and Supplementary Fig. 4 ), providing strong evidence for the involvement of 3ABA-ACP and 3AP-3OP-ACP in pactamycin biosynthesis.
Isolation of GlcNAc-3AAP from complemented mutants.
While 3AP-3OP-SNAC was able to complement the lack of 3ABA in ΔptmH/ΔptmT and rescued the production of TM-025 and TM-026 in the mutant, it was not able to recover the production of pactamycin or TM-025/TM-026 when added to the cultures of ΔptmS resistant gene aac (3) IV. This suggests that the discrete PKS proteins may work together and that the synthetic β-ketoacyl intermediate has to be initially loaded onto PtmI, presumably through the ketosynthase PtmK (Fig. 2g) . Instead of recovering the production of pactamycin or TM-025/TM-026, the addition of 3AP-3OP-SNAC to these mutants led to another product with a molecular formula of C 16 Note 2) confirmed the identity of the product to be GlcNAc-3AAP (6) . This product may be formed from unspecific hydrolysis of the NAC thioester, and the resulting β-ketoacid undergoes non-enzymatic decarboxylation to give 3AAP, which is subsequently glycosylated by the glycosyltransferase PtmJ to give GlcNAc-3AAP (Fig. 2g) . The accumulation of GlcNAc-3AAP in the culture suggests that it is not an intermediate in pactamycin biosynthesis as previously suggested 2 . This was further confirmed by adding GlcNAc-3AAP to cultures of ΔptmH/ ΔptmT and ΔptmJ mutants, in which no recovery of pactamycin production was observed. Similarly, incorporation experiments with 3AAP in cultures of ΔptmH/ΔptmT and ΔptmJ mutants also did not give any pactamycin products, confirming that 3AAP and GlcNAc-3AAP are not involved in the pactamycin pathway.
To determine whether glycosylation occurs before the PKS reaction (that is, on 3ABA), GlcNAc-3ABA (13) was synthesized (Supplementary Note 3) and added to cultures of ΔptmH/ΔptmT and ΔptmJ mutants. MS analysis of the culture broths showed the recovery of pactamycin analog production in the ΔptmH/ΔptmT mutant, but paradoxically no pactamycin production was observed in the ΔptmJ mutant ( Supplementary Fig. 7 ). As GlcNAc-3ABA was not able to salvage the production of pactamycin without the presence of the glycosyltransferase PtmJ, it may be assumed that the compound was not incorporated into the pathway intact. Indeed, doubly isotope-labeled [ Supplementary Fig. 8 ). Therefore, it may be concluded that [ Fig. 8 ). This isotope experiment not only explains why GlcNAc-3ABA was not able to rescue the production of pactamycin in the ΔptmJ mutant, but also excludes the possibility that glycosylation occurs before the polyketide formation.
In vitro characterization of PtmS. To demonstrate explicitly the involvement of the discrete PKS proteins PtmS, PtmI, PtmK and PtmO in the formation of the 3AAP moiety, the genes were cloned and the products were characterized in vitro. The putative AMPforming acyl-CoA synthetase PtmS was predicted to catalyze the activation of the starter unit 3ABA to its AMP derivative. Therefore, the gene was cloned into a pMBP28b vector and expressed in E. coli BL21(DE3)pLysS to obtain soluble His6-tagged maltose binding protein-fused PtmS ( Supplementary Fig. 9 ). Subsequently, the purified protein was incubated with 3ABA in the presence of ATP and MgCl 2 to give 3-aminobenzoyl-AMP (3ABA-AMP), which was validated by high-peformance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) ( Supplementary Fig. 10 ), confirming the function of PtmS as an AMP-ligase (Fig. 3a) . The relative yield of 3ABA-AMP, estimated from the amount of inorganic diphosphate produced in the reaction 15, 16 , was ~63% ( Supplementary Fig. 11 ).
PtmI serves as a carrier for 3ABA and malonyl unit. As ptmI is the only gene encoding a discrete ACP within the pactamycin biosynthetic gene cluster, we propose that PtmI would act as a carrier protein for both the 3ABA starter unit and the malonyl extender unit. A putative 4'-phosphopantetheinyl transferase (PPTase) gene, ptmP, was also found in the cluster, suggesting its role in converting the inactive apo-PtmI to the active holo-PtmI. PtmP may also be responsible for the activation of the ACP domain of PtmQ. The latter protein shares high similarity with the iterative type I PKS, ChlB1, which is involved in the biosynthesis of 6-methylsalicylic acid (6MSA) in S. antibioticus 17 . Gene inactivation and heterologous expression experiments have confirmed the activity of PtmQ as a 6MSA synthase 3 .
To determine the function of PtmI, the gene was cloned in pACYCDuet-1, independently and together with the putative PPTase gene ptmP, and expressed in E. coli BL21(DE3)pLysS. While the expression of ptmI could be induced by isopropyl-β-d-thiogalactoside (IPTG) to give soluble recombinant PtmI ( Fig. 3b and Supplementary Fig. 12 ), no clear expression of ptmP was observed. Subsequently, the broad-spectrum PPTase gene sfp from Bacillus subtilis was cloned in pET28a expression vector and soluble recombinant Sfp was obtained ( Supplementary Fig. 9) . The construct was then introduced into E. coli BL21(DE3)pLysS that harbors pACYCDuet-1/ptmI to give soluble Sfp and holoPtmI (12,393.50 Da) as confirmed by HPLC ( Supplementary  Fig. 12 ) and LC-MS (Fig. 3c ). Post-translational gluconoylation (Gluc) of the holo-PtmI was also observed (12,571.50 Da). The holo-PtmI and its Gluc analog were then incubated with PtmS and 3ABA for 7 h to give 3ABA-PtmI (12,513. amount of AMP produced in the reaction) 18 ( Fig. 3d and Supplementary Fig. 13 ).
Incubation of the holo-PtmI with malonyl-CoA ( Fig. 3a ) also led to the formation of malonyl-PtmI (12,479.90 Da) and its Gluc analog (12,658.00 Da) (Fig. 3e) , confirming the role of PtmI as a carrier protein for both 3ABA and malonyl moieties. This set the stage for a subsequent coupling reaction between the 3ABA starter unit and the malonyl extender unit by a putative β-ketoacyl-ACP synthase, PtmK.
Characterization of the β-ketoacyl-ACP synthase (KAS) PtmK.
PtmK is similar to KAS I and II, which are responsible for the elongation steps in fatty acid biosynthesis 11, 12 . Since isotope incorporation experiments have shown that the methyl group present in the 3AAP unit is derived from C-2 of acetate, PtmK has been predicted to be involved in this extension. To characterize the function of PtmK, the gene was cloned into pET28a and expressed in a tunable T7 expression strain, E. coli Lemo21(DE3), to provide soluble His 6 -tagged PtmK, which was then purified by a nickel-NTA column ( Supplementary Fig. 9 ). Incubation of PtmK with 3ABA-PtmI for 12 h, followed by incubation with malonyl-PtmI for 16 h yielded a mass consistent with 3-(3-aminophenyl)3-oxopropionyl-PtmI (12,555.20 Da) (Fig. 3f) , demonstrating the involvement of discrete PKS proteins in the formation of the 3AAP moiety of pactamycin. It is worth noting that acetyl-PtmI (12,436.60 Da), a decarboxylation product of malonyl-PtmI, was substantially produced in the reaction mixture ( Fig. 3f) , indicating a high tendency of protonation of the decarboxylated intermediate. This was only conspicuously observed when PtmK was present and further validates the decarboxylative activity of PtmK.
PtmO is responsible for premature release of 3AP-3OP. The formation of GlcNAc-3AAP from 3AP-3OP-SNAC in the cultures of ΔptmS, ΔptmI, ΔptmK, ΔptmH/ΔptmI and ΔptmH/ptmK::aac(3) IV mutants may be due to unspecific hydrolysis of the NAC thioester by the putative hydrolase PtmO, followed by non-enzymatic decarboxylation. The product is then glycosylated by PtmJ to generate the shunt metabolite GlcNAc-3AAP. To confirm this, 3AP-3OP-SNAC was added to a culture of the ΔptmO mutant. As expected, the mutant neither produced pactamycin nor GlcNAc-3AAP ( Supplementary  Fig. 14) , supporting the hydrolytic function of PtmO and its role in pactamycin biosynthesis. This was subsequently confirmed by incubating 3AP-3OP-PtmI with purified recombinant PtmO, which gave 3AAP as a product (Fig. 4) . No product was observed when boiled PtmO was used (Fig. 4b) , which unambiguously established that PtmO is a hydrolase, and that the β-ketoacid product can undergo a spontaneous decarboxylation reaction. This is consistent with our observation that synthetically prepared 3AP-3OP can convert to 3AAP without an enzyme. However, as 3AAP and its glycosylated product are not involved in pactamycin biosynthesis, the timing of this hydrolysis remains unclear, but it should occur later in the pathway after further modification(s) of 3AP-3OP-PtmI.
PtmJ is a promiscuous glycosyltransferase. Although GlcNAc-3AAP is not an intermediate in the pactamycin pathway, its production by the S. pactum strains when incubated with 3AAP indicates the relaxed substrate specificity of PtmJ. In addition to 3AAP, PtmJ can also glycosylate phenylamines such as aniline, 3-fluoroaniline (3FAN) and 4-fluoroaniline (4FAN). Addition of these compounds to the cultures of ΔptmH/ΔptmT mutant resulted in the production of GlcNAc-AN, GlcNAc-3FAN and GlcNAc-4FAN ( Supplementary  Figs. 15 and 16) . Some of the products were isolated chromatographically and their chemical structures were characterized by nuclear magnetic resonance (NMR) ( Supplementary Figs. 17 and  18 ). Besides the GlcNAc products, glucosyl aniline (Glc-AN), Glc-3FAN and Glc-4FAN ( Supplementary Figs. 15 and 16 ) were also produced, suggesting that PtmJ not only recognizes NDP-GlcNAc, but also NDP-glucose, as a donor sugar. Addition of 3AAP and 4FAN individually to cultures of the ΔptmJ mutant 3 did not give any glycosylated 3AAP or 4FAN ( Supplementary Figs. 19 and 20) , ruling out the possibility that other glycosyltransferases are involved in the reaction and confirming that PtmJ is the sole enzyme responsible for the formation of the glycosylated arylamines. Despite its structure similarity to 3AAP, 3ABA was not processed by PtmJ (Supplementary Fig. 21 ).
The timing of glycosylation in pactamycin biosynthesis. As neither 3ABA nor 3AAP is the natural substrate for PtmJ, the glycosylation reaction is predicted to take place during the conversion of 3ABA to the 3AAP moiety, which involves the discrete PKS enzymes PtmS, PtmI and PtmK (Fig. 3) . Therefore, it may be proposed that the substrate for PtmJ is an ACP-bound polyketide intermediate. To determine whether PtmJ is able to catalyze the glycosylation of 3ABA-ACP and/or 3AP-3OP-ACP in vitro, the gene was cloned in pET28a and expressed in E. coli Lemo21(DE3) to give soluble His 6 -tagged PtmJ. The purified protein was subsequently incubated with 3ABA-ACP or 3AP-3OP-ACP for 10 h in the presence of UDP-GlcNAc. 3ABA-ACP was generated in a one-pot reaction containing 3ABA, PtmS, PtmI/Sfp, ATP and MgCl 2 for 7 h (Fig. 5a) , whereas 3AP-3OP-ACP was generated from the same one-pot reaction condition but with subsequent incubation with PtmK for 12 h followed by incubation with malonyl-ACP for 16 h. LC-MS analysis of the reaction mixtures containing PtmJ revealed the formation of GlcNAc-3ABA-ACP (12,716.20 Da) (Fig. 5b) and GlcNAc-3AP-3OP-ACP (12,758.40 Da) (Fig. 5c) (Fig. 5d) , which unambiguously demonstrated the formation of glycosylated 3ABA-ACP and 3AP-3OP-ACP. Reaction mixtures containing boiled PtmJ did not produce any glycosylated products (Fig. 5e) , confirming the role of PtmJ in the glycosylation reactions. This is direct evidence for the glycosylation of an ACP-bound polyketide intermediate in natural product biosynthesis. The relative yield of GlcNAc-3ABA-PtmI, as estimated from the amount of UDP produced in the reaction measured by the coupled colorimetry assay using pyruvate kinase and lactate dehydrogenase 19 , was ~58% ( Supplementary Fig. 22 ). On the other hand, the average yield of GlcNAc-3AP-3OP-ACP, as estimated from the mass spectral data, was about 36% (Supplementary Table 2 ).
PtmK functions as a gatekeeper. Although PtmJ can glycosylate both 3ABA-ACP and 3AP-3OP-ACP in vitro, it may be contemplated that only one of these compounds is the preferred natural substrate for the enzyme. Moreover, our study above has shown that the ketosynthase PtmK can catalyze a Claisen condensation between 3ABA-ACP and malonyl-ACP to give 3AP-3OP-ACP, but it was not clear whether PtmK can process glycosylated 3ABA-ACP (GlcNAc-3ABA-ACP) to give GlcNAc-3AP-3OP-ACP. Accordingly, a set of experiments was designed to investigate the substrate specificity of PtmK and evaluate whether GlcNAc-3ABA-PtmI can be processed by the enzyme. While GlcNAc-3ABA-PtmI may be produced from 3ABA-PtmI using PtmJ and UDP-GlcNAc, the product needed to be separated from the unreacted 3ABA-PtmI, PtmJ or UDP-GlcNAc before subjecting it to the subsequent reactions, as the presence of the remaining 3ABA-PtmI in the mixture may be processed by PtmK and subsequently by PtmJ to give GlcNAc-3AP-3OP-PtmI. However, attempts to separate GlcNAc-3ABA-PtmI from PtmJ or UDP-GlcNAc using size-exclusion filters were not successful. Therefore, 3ABA-SNAC, which resembles 3ABA-ACP, was used to produce GlcNAc-3ABA-SNAC, which was then separated, together with the remaining 3ABA-SNAC, from MeOH-denatured PtmJ (Fig. 6a,b) . Incubation of 3ABA-SNAC and GlcNAc-3ABA-SNAC with PtmK for 12 h followed by 16 h incubation with malonyl-PtmI only gave 3AP-3OP-PtmI (β-ketoacyl-ACP) (Fig. 6c) , revealing that only 3ABA-SNAC was processed by PtmK, whereas GlcNAc-3ABA-SNAC was not. Therefore, while 3ABA-PtmI can be glycosylated by PtmJ in vitro, the product cannot be processed by the ketosynthase PtmK, suggesting that only glycosylation of the ACP-bound β-keto intermediate 3AP-3OP-PtmI is relevant to pactamycin biosynthesis.
Discussion
3-Aminobenzoic acid (3ABA) is a small molecule commonly used in synthetic organic chemistry, but its occurrence in nature is extremely rare 5, 6 . In pactamycin biosynthesis, 3ABA has been shown to be the precursor of the 3AAP moiety, but details of the transformation including enzymes that are involved in the transformation were elusive 4, 5, 20 . In this study, we show that the conversion of 3ABA to the 3AAP moiety is catalyzed by a set of discrete PKS enzymes, PtmS, PtmI, PtmK and PtmO. PtmS is an adenylate-forming enzyme 21 that converts 3ABA to 3ABA-AMP; the product is then loaded onto the ACP PtmI. PtmS shares moderate sequence similarity to the adenylation domains in the loading modules of the rifamycin and ansamitocin PKSs (31.5% identity with the RifA adenylation domain and 31.1% identity with the AsmA adenylation domain) 22, 23 . These domains are part of multifunctional multimodular type I PKSs that convert 3-amino-5-hydroxybenzoic acid (AHBA) to AHBA-AMP, which is then loaded onto the ACP domains of the enzymes 23, 24 . PtmK is similar to β-ketoacyl-ACP synthases (KAS) I/II, which are responsible for the elongation steps in fatty acid biosynthesis 11, 12 . Another stand-alone KAS protein (PtmR) in the pathway was also considered as a candidate enzyme involved in 3AAP formation; however, an earlier study revealed that this protein is involved in the tailoring process of pactamycin 10 . While PtmS, PtmI and PtmK are discrete PKS proteins, they also appear to function more effectively when working together, which is consistent with some other discrete PKS proteins 25, 26 . The ability of 3AP-3OP-SNAC to rescue the production of TM-026 in a ΔptmH/ ΔptmT strain but not in mutant strains lacking any of the PKS genes supports this notion. However, our study also shows that the loading of malonyl to PtmI can take place by its intrinsic self-acylation property. Further detailed studies are necessary to illuminate the nature of interactions between these discrete polyketide proteins.
Although 3AAP and GlcNAc-3AAP have been proposed to be part of pactamycin biosynthesis 2 , these compounds appeared to have no direct involvement in the pathway. Incorporation experiments and biochemical studies have also ruled out the possibility of glycosylation of 3ABA. On the other hand, 3ABA-SNAC and 3AP-3OP-SNAC, which resemble ACP-bound substrates, were both able to rescue the production of TM-025/TM-026 in ΔptmH/ ΔptmT, indicating the role of the PKS in 3AAP formation. While it is possible that 3ABA-SNAC is hydrolyzed to 3ABA before incorporation into the pathway, hydrolysis of 3AP-3OP-SNAC and spontaneous decarboxylation would result in 3AAP, which is not involved in pactamycin biosynthesis. Therefore, the production of TM-026 by ΔptmH/ΔptmT when incubated with 3AP-3OP-SNAC strongly suggests that 3AP-3OP-ACP is indeed involved in the pathway and the glycosylation reaction should take place on an ACP-bound polyketide intermediate.
The above results were validated by reconstituted enzymatic assays using purified recombinant PtmS, PtmI, PtmK, PtmJ and PtmO. The formation of 3AP-3OP-PtmI from a concerted catalytic function of PtmS, PtmI and PtmK strongly suggests that 3AP-3OP-PtmI is involved in the pactamycin pathway. The PtmI-bound intermediate is then glycosylated by the glycosyltransferase PtmJ. This is an unusual phenomenon that so far has not been reported to the best of our knowledge. Although in the in vitro assay, PtmJ can also glycosylate 3ABA-PtmI, the glycosylated product is not processed by the subsequent enzyme, the ketosynthase PtmK. Thus, PtmK appears to function as a gatekeeper that only selects 3ABA-PtmI for the Claisen condensation. This result strongly suggests that in pactamycin biosynthesis, glycosylation takes place after the formation of 3AP-3OP-PtmI. While there is no evidence to negate the possibility that the glycosylation of 3ABA-PtmI may also occur in vivo, one would expect that such unproductive biotransformation would be regulated by negative feedback and/or equilibrium between biosynthetic intermediates 27 . Furthermore, the fact that GlcNAc-3AAP is not directly involved in pactamycin biosynthesis also suggests that additional modifications of the sugar moiety are required before the glycosylated β-ketoacyl product is cleaved from the ACP. These modifications may involve the oxidoreductase PtmN, the aminotransferase PtmA, the carbamoyltransferase PtmB, the deacetylase PtmG, the radical SAM-dependent C-methyltransferases PtmL and PtmM and/or rearrangement and cyclization to an aminocyclopentitol intermediate by the radical SAM protein PtmC 2, 3, 28 . PtmJ is a putative GT-A type protein belonging to family 2 of the glycosyltransferase superfamily. Members of this family include chitin synthases, N-acetylglucosaminyltransferases and hyaluronan synthases 29 . However, basic local alignment search tool (BLAST) analysis indicated that there are only a few proteins reported in the NCBI database that are similar to PtmJ. The most similar ones are putative glycosyltransferases from Streptomyces sp. (WP_079057159.1, 71.20% identity), Streptomyces acidiscabies (WP_078841237.1, 72.76% identity) and Streptomyces griseoruber (WP_099054043.1, 68.71% identity), which also seem to be part of the pactamycin clusters in those organisms. PtmJ is highly promiscuous with the ability to not only glycosylate small molecules but also protein-bound substrates. In fact, many enzymes in the pactamycin pathway have broad substrate specificity. Those include the N-methyltransferase PtmD, the acyltransferase PtmR and the 7-hydroxylase, for which the gene is still unknown 9, 10 . However, the ability of PtmJ to catalyze the glycosylation of a polyketide intermediate while it is still attached to an ACP is unprecedented.
In conclusion, this study reveals insights into the formation of the 3AAP moiety of pactamycin involving a set of discrete PKS proteins, and demonstrates the glycosylation of an ACP-bound polyketide intermediate by a highly promiscuous glycosyltransferase, PtmJ. In addition, we validated that PtmO is a hydrolase enzyme that is responsible for the release of the glycosylated β-ketoacid product from the ACP, and the free β-ketoacid subsequently undergoes decarboxylation.
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Methods
General. All chemicals were obtained from Sigma-Aldrich, EMD, TCI or Pharmacia. All reactions were carried out under an inert, argon atmosphere in oven-dried glassware at 170 °C unless indicated otherwise. Benzene (PhH), methylene chloride (CH 2 Cl 2 ) and triethylamine (Et 3 N) were distilled over calcium hydride before use. All other reagents and solvents were used without further purification from commercial sources. Analytical thin-layer chromatography (TLC) was performed using silica gel plates (60 Å), which were visualized using an ultraviolet (UV) lamp, ceric ammonium molybdate, potassium permanganate, iodine or vanillin stains. Chromatographic purification of products was performed on silica gel (60 Å, 72-230 mesh). Proton NMR spectra were recorded on Bruker 400, 500 or 700 MHz spectrometers. Proton chemical shifts are reported in ppm (δ) relative to the residual solvent signals as the internal standard. Multiplicities in the 1 H NMR spectra are described as follows: s, singlet; bs, broad singlet; d, doublet, bd, broad doublet; t, triplet; bt, broad triplet; q, quartet and m, multiplet: coupling constants are reported in Hz. Carbon NMR spectra were recorded on Bruker 500 or 700 MHz spectrometers. Carbon chemical shifts are reported in ppm (δ) relative to the residual solvent signals as the internal standard. Low-resolution ESI mass spectra were recorded on a Thermo-Finnigan liquid chromatographion trap mass spectrometer. High-resolution ESI mass spectra were recorded on a ThermoElectron LTQ-Orbitrap Discovery mass spectrometer with a dedicated Accela HPLC system. FT-IR spectra were obtained on NaCl plates with a PerkinElmer Spectrum Vision spectrometer.
General DNA manipulations. Genomic DNA of S. pactum ATCC 27456 was prepared by standard protocol 30 or using the DNeasy Tissue Kit (QIAGEN). DNA fragments were recovered from an agarose gel by using the QIAquick Gel Extraction Kit (QIAGEN). Restriction endonucleases were purchased from Invitrogen or Promega. Preparation of plasmid DNA was done by using a QIAprep Spin Miniprep Kit (Promega). All other DNA manipulations were performed according to standard protocols 30, 31 . PCR was performed in 30 cycles by using a Mastercycler gradient thermocycler (Eppendorf) and Platinum Taq high fidelity DNA polymerase (Invitrogen). Oligodeoxyribonucleotides for PCR primers were synthesized by Sigma-Genosys. The nucleotide sequences of the gene fragments were determined at the Center for Genome Research and Biocomputing Core Laboratories, Oregon State University. ORFs were analyzed by FramePlot 32 analysis and the BLAST program 33 .
Bacterial strains, plasmids, culture techniques and media. Pactamycin producing S. pactum ATCC 27456 was purchased from ATCC. S. pactum and its derivatives were grown on BTT agar (glucose (1%), yeast extract (0.1%), beef extract (0.1%), casein hydrolysate (0.2%), agar (1.5%), pH 7.4) at 30 °C for 3 d. Single colonies were used to inoculate the BTT seed cultures and incubated at 30 °C for 3 d. Production cultures were prepared in modified Bennett medium and inoculated with seed cultures (10% (v/v)) 3 . The production cultures were incubated at 30 °C for 5 d under vigorous shaking (200 r.p.m.). Escherichia coli DH10B was used as a host strain for the construction of recombinant plasmids. E. coli ET12567 (pUZ8002) was used as donor strain in conjugation experiments. pBlueScript II (SK-) (Stratagene) and pGEM-T Easy (Promega) were used as cloning vectors. pTMN002, a pJTU1278 + derivative containing apramycinresistance cassette, was used as vector for gene inactivation 3, 34 . E. coli BL21(DE3) pLysS and E. coli Lemo21(DE3) were used as heterologous hosts for recombinant protein production. All bacterial strains and plasmids used in this study are listed in Supplementary Tables 3 and 4 . Construction, genetic complementation and analysis of ΔptmS, ΔptmI, ptmK::aac(3)IV, ΔptmO and ΔptmJ mutants have been described in our previous publications 3, 10 .
Construction of ΔptmH/ΔptmI, ΔptmH/ptmK::aac(3)IV and ΔptmH/ΔptmO mutants. The target genes were inactivated using gene in-frame deletion strategy (Supplementary Fig. 1a) . Two ~1 kilobase PCR fragments upstream (HindIII/EcoRI) and downstream (EcoRI/XbaI) of the ptmI or ptmO genes were fused and cloned into the HindIII/XbaI sites of pBluescript II SK(-) vector. The PCR products of ptmI and ptmO were excised and cloned into the HindIII/XbaI sites of pTMN002 to generate pTMM052 and pTMM08, respectively. All plasmids were then individually introduced into the ΔptmH mutant strain of S. pactum by conjugation using the E. coli donor strain ET12567/pUZ8002. Apramycin resistant strains representing single crossover mutants were obtained and subsequently grown on BTT agar plates containing apramycin (50 μg ml
−1
). Apramycin sensitive colonies were counter-selected by replica plating on BTT agar with and without apramycin (50 μg ml
). The resulting double-crossover candidate strains were confirmed by PCR amplification with F1 and R2 primers flanking the respective targeted gene (Supplementary Fig. 2) .
Construction of ΔptmH/ptmK::aac(3)IV. The ptmK gene (1.7 kb) was inactivated using a gene disruption strategy (Supplementary Fig. 1b) . The internal fragment (0.88 kb) of ptmK was generated by PCR using a forward primer containing a HindIII site and a reverse primer containing a Xbal site (Supplementary Table 5 ), and S. pactum genomic DNA as a template. The PCR product was cloned into the HindIII/Xbal sites of pTMN002 to generate pTMM055. Plasmid pTMM055 was introduced into the S. pactum ΔptmH strain by conjugation, as described by Lu et al. 14 . The freshly harvested spores and the overnight-grown E. coli ET12567/pUZ8002 containing plasmid pTMM055 were mixed and plated onto MS agar plates containing MgCl 2 (10 mM). After incubation at 30 °C for 18 h, the plates were overlaid with sterile water (1 ml) containing nalidixic acid (1 mg ml
) and apramycin (1 mg ml −1 ) and incubated at 30 °C for 5-7 d. The exconjugant (single crossover) colonies were purified by plating onto BTT agar plates supplemented with apramycin (50 μg ml
). Disruption of ptmK was confirmed by PCR amplification (Supplementary Fig. 2 ).
Analysis of ΔptmH/ΔptmI, ΔptmH/ΔptmO and ΔptmH/ptmK::aac(3) IV mutant strains metabolic profiles. The ΔptmH/ΔptmI, ΔptmH/ΔptmO and ΔptmH/ptmK::aac(3)IV strains were grown on BTT agar at 30 °C for 3 d. Single colonies were used to inoculate the BTT seed cultures (medium for ΔptmH/ptmK::aac(3)IV was supplemented with apramycin (10 μg ml
) and ampicillin (20 μg ml −1 )) and incubated at 30 °C for 2 d. Production cultures were prepared in modified Bennett's medium (50 ml) 3 and inoculated with seed cultures (10% (V/V)). The production cultures were incubated at 30 °C for 5 d under vigorous shaking (200 r.p.m.). The mycelia were centrifuged and the supernatants were extracted twice with equal volumes of EtOAc followed by extraction with n-BuOH. The organic solvent from each extraction was evaporated in vacuo and the residues dissolved in MeOH and analyzed by ESI-MS. The phenotypes and products are listed in Supplementary Table 6 . , ΔptmH/ ΔptmI, ΔptmH/ΔptmO and ΔptmH/ΔptmK::aprR mutant strains were streaked on BTT agar (glucose (1%), yeast extract (0.1%), beef extract (0.1%), casein hydrolysate (0.2%), agar (1.5%), pH 7.4) and incubated at 30 °C for 3 d. Spores of the mutant strains were grown in Erlenmeyer flasks (125 ml) each containing 30 ml seed medium (glucose (1%), yeast extract (0.1%), beef extract (0.1%), casein hydrolysate (0.2%), pH 7.4) for 3 d at 28 °C and 200 r.p.m. The seed cultures of each strain (1 ml each) were used to inoculate 2 × 50 ml Erlenmeyer flasks containing production medium, modified Bennett medium (glucose (1%), yeast extract (0.1%), beef extract (0.1%), soytone (0.2%), pH 7.4) (10 ml in each flask). After incubation for 16 h under the same condition, each mutant strain was fed with 3.0 mM of 3AP-3OP-SNAC and the last flask of each strain was used as a control (no feeding). The feeding was repeated every 12 h for 2 d. After 5 d of incubation, the cultures were centrifuged and the metabolites of each group were extracted twice with equal volume of EtOAc and once with 1.5 vol. of n-BuOH. The organic solvent was evaporated in vacuo. The residues were dissolved in MeOH and were analyzed by MS and HPLC. The phenotypes and products are listed in Supplementary Table 6 .
Chemical complementation of
Other incorporation studies with 3ABA-SNAC, GlcNAc-3ABA, [
13 C]GlcNAc-[ 13 C]3ABA, aniline, 3-fluoroaniline, 4-fluoroaniline and 3AAP to various mutants of S. pactum were carried out using a similar procedure to that described above.
Cloning and expression of ptmS. The ptmS gene was amplified using the primers ptmS-EcoRI and ptmS-HindIII (Supplementary Table 5 ). The PCR product was cloned into the EcoRI and HindIII sites of pMBP-28 B to generate the expression vector pMBP-28 B-ptmS, which was then transferred into E. coli BL21(DE3)pLysS (Invitrogen). The empty vector pMBP-28 B was introduced into E. coli BL21(DE3) pLysS to be used as a control. For expression of MBP-PtmS fusion protein, the bacteria were grown in LB medium supplemented with kanamycin (50 μg ml Cloning and expression of ptmI, ptmP and sfp. The ptmI gene was amplified using the primers ptmI-EcoRI and ptmI-HindIII (Supplementary Table 5 ). The PCR product was cloned into the EcoRI and HindIII sites of pACYCDuet-1 to generate the expression vector pACYCDuet-1-ptmI. For co-expression of PtmI and PtmP (to obtain holo-PtmI), the ptmP gene was amplified using the primers ptmP-NdeI and ptmP-XhoI and the PCR product was cloned into the NdeI and XhoI sites of the pACYCDuet-1-ptmI construct to produce the expression vector pACYCDuet-1-ptmI-ptmP. On the other hand, the sfp gene was amplified using the primers sfp-NdeI and sfp-XhoI and the plasmid pUC8-sfp was used as a template. The PCR product was cloned into the NdeI and XhoI sites of pET28a to generate the expression vector pET28a-sfp. Each expression plasmid was transferred into E. coli BL21(DE3). In addition, to obtain holo-PtmI, both pACYCDuet-1-ptmI and pET28a-sfp were transferred into E. coli BL21(DE3). For the expression of apoPtmI, the E. coli BL21(DE3) harboring pACYCDuet-1-ptmI construct was grown in LB medium supplemented with chloramphenicol (50 μg ml −1 ) at 37 °C for 16 h. An aliquot (2 ml) of overnight-grown culture were used to inoculate a fresh LB medium (200 ml in a 1,000 ml flask), supplemented with the same antibiotic, and was grown at 37 °C with shaking (200 r.p.m.) until an OD 600 of 0.5 was reached. Then, the temperature was reduced to 30 °C and IPTG was added to a final concentration of 0.3 mM to induce protein expression. After further growth for 8 h, the cells were collected by centrifugation (4,200 r.p.m., 10 min, 4 °C) and stored at −80 °C until used. The PtmI was co-expressed with PtmP and Sfp individually using the same protocol of Apo-PtmI expression described above.
Cloning and expression of ptmK. The ptmK gene was amplified using the primers ptmK-EcoRI and ptmK-HindIII (Supplementary Table 5 ). The PCR product was cloned into the EcoRI and HindIII sites of pET28a to generate the expression vector pET28a-ptmK. The pET28a-ptmK construct was transferred into E. coli Lemo21 (Invitrogen). The empty vector pET28a was also transferred into E. coli Lemo21 to be used as a control. To express ptmK, the E. coli Lemo21 harboring pET28a-ptmK was cultivated in LB medium supplemented with kanamycin (50 μg ml −1 ) and chloramphenicol (50 μg l −1 ) at 37 °C for 16 h. Subsequently, the overnight-grown culture (2 ml) was transferred to a fresh LB medium (200 ml in 1,000 ml flask), supplemented with kanamycin (50 μg ml −1 ), chloramphenicol (50 μg ml −1 ) and l-rhamnose (80 µM) and grown at 37 °C until OD 600 reached 0.5. Then, the temperature was reduced to 30 °C and IPTG was added to a final concentration of 0.4 mM to induce protein expression. After further growth for 10 h, the cells were collected by centrifugation (4,200 r.p.m., 10 min, 4 °C) and stored at −80 °C until used.
Cloning and expression of ptmO. The ptmO gene was amplified using the primers ptmO-BglII and ptmO-EcoRI (Supplementary Table 5 ). The PCR product was cloned into the BamHI and EcoRI sites of the pRSET B to generate the expression vector pTMM080 (pRSET B-ptmO), which was then introduced into E. coli BL21(DE3)pLysS (Invitrogen). The empty vector pRSET B was also introduced into E. coli BL21(DE3)pLysS and used as a control. For the expression of ptmO, the bacteria were grown in LB medium supplemented with chloramphenicol (50 μg ml −1 ) and ampicillin (100 μg ml −1 ) at 37 °C for 16 h. An aliquot (2 ml) of the overnight-grown culture was used to inoculate a fresh LB medium (200 ml in a 1,000 ml flask), supplemented with the same antibiotics, at 37 °C with shaking (200 r.p.m.) and was grown until an OD 600 of 0.5 was reached. Then, the temperature was reduced to 30 °C and IPTG was added to a final concentration of 0.3 mM to induce protein expression. After further growth for 8 h, the cells were collected by centrifugation (4,200 r.p.m., 10 min, 4 °C) and stored at −80 °C until used.
Cloning and expression of ptmJ. The ptmJ gene was amplified using the primers ptmJ-NdeI and ptmJ-EcoRI. The PCR product was cloned into the NdeI and EcoRI sites of pET28a and was subsequently transferred into E. coli Lemo21(DE3). For the expression of ptmJ, the bacteria were grown in LB medium supplemented with chloramphenicol (50 μg ml −1 ) and kanamycin (50 μg ml −1 ) at 37 °C for 16 h. An aliquot (2 ml) of the overnight-grown culture was used to inoculate a fresh LB medium (200 ml in a 1,000 ml flask), supplemented with kanamycin (50 μg ml −1 ), chloramphenicol (50 μg ml −1 ) and l-rhamnose (80 µM) and grown at 37 °C with shaking (200 r.p.m.) until an OD 600 of 0.5 was reached. Then, the temperature was reduced to 30 °C and IPTG was added to a final concentration of 0.4 mM to induce protein expression. After further growth for 10 h, the cells were collected by centrifugation (4,200 r.p.m., 10 min, 4 °C) and stored at −80 °C until used.
Enzyme assay of PtmS. PtmS assay was done in a reaction (100 µl) containing Tris-HCl (50 mM, pH 8.0), ATP (5 mM), MgCl 2 (5 mM), DTT (1 mM), 3ABA (2 mM) and PtmS (10 µM). The reaction was performed at 30 °C for 5 h. The reaction was then quenched with an equal volume of MeOH, centrifuged and the supernatant (20 µl) was analyzed by LC-MS (Zorbax SB-C18 column, 4.6 × 150 mm, 5 µm; solvent A: H 2 O (contains 0.1% TFA), solvent B: CH 3 CN (contains 0.1% TFA), gradient 2-100% solvent B over 55 min; flow rate 0.5 ml min −1 ). The measurement of inorganic pyrophosphate (PP i ) production was performed using a coupled colorimetric assay using pyrophosphatase and purine nucleoside phosphorylase. The PtmS enzymatic reaction solutions (5 or 10 μl) were added to the enzyme solution containing pyrophosphatase (5 μl) and purine nucleoside phosphorylase (10 μl), MESG (200 μl), 50× buffer (50 μl) and ddH 2 O (up to 1,000 μl). The mixture was then incubated for 1 h at 22 °C. The change in absorbance at 360 nm was obtained in triplicate from distinct samples after subtracting the background absorbance.
Formation of 3-aminobenzoyl-PtmI. PtmS assay was done in a reaction (100 µl) containing Tris-HCl (50 mM, pH 8. ). Boiled PtmS was used as a negative control.
The measurement of AMP production was performed using the AMP-Glo assay (Promega). The PtmS/PtmI enzymatic reaction solutions (10 μl) were diluted with Tris-HCl buffer (15 μl), mixed with the AMP-Glo Reagent I (25 μl) and incubated for 60 min to terminate the reaction, remove any remaining ATP and convert AMP to ADP. Subsequently, AMP detection solution (a mixture of AMP-Glo Reagent II and Kinase-Glo One Solution) (50 μl) was added to the mixture and incubated for 60 min to drive the conversion of ADP to ATP. The ATP was detected through the luciferase reaction. The change in luminescence was obtained in triplicate from distinct samples after subtracting the background emission using BioTek Synergy HT microplate reader with the Gen5 v.2.07 software.
Malonylation of the ACP PtmI. Malonylation of PtmI was achieved by incubation of PtmI (200 μM in 50 mM Tris-HCl, 500 mM NaCl, pH 8.0) with malonyl-CoA (8 mM) for 7 h at 30 °C. The reaction was processed and analyzed by LC-MS as described for 3-aminobenzoyl-PtmI above.
Enzyme assay of PtmK (formation of β-ketoacyl-PtmI). PtmK (20 µM) was preacylated by incubation with 3ABA-PtmI at 30 °C for 12 h. Then the acyl-PtmK was mixed with malonyl-PtmI in a 1:1 ratio. The reaction was allowed to proceed for 16 h and the product was analyzed by LC-MS as described above.
Enzyme assay of PtmO. After formation of β-ketoacyl-PtmI, the hydrolase enzyme PtmO was added to the reaction mixture and incubation was extended at 30 °C for 7 h. The reaction was quenched by adding an equal volume of MeOH, centrifuged and the product was analyzed by HPLC.
Enzyme assay of PtmJ. After the formation of 3ABA-PtmI or β-ketoacyl-PtmI, the glycosyltransferase enzyme PtmJ (10 µM), UDP-GlcNAc (5 mM) and MgCl 2 (2 mM) were added and the reaction mixtures were incubated at 30 °C for 10 h. The products were analyzed by LC-MS as described above.
The UDP production was determined by using the phosphopyruvate kinase and lactate dehydrogenase coupled assay (Sigma-Aldrich). The reaction mixture (200 μl) contained PtmJ reaction mixture (150 μl), phosphoenolpyruvate (1.6 mM), reduced nicotinamide adenine dinucleotide (NADH) (0.1 mM), phosphopyruvate kinase (37 U) and lactate dehydrogenase (55.8 U). Oxidation of NADH to NAD + was monitored in a 96-well plate using a spectrophotometric microplate reader at 340 nm. Reaction mixtures with boiled PtmJ were used as negative control (blank). The data were collected in triplicate from distinct samples.
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